Breaking News
December 13, 2018 - Research findings could lead to new targets for cancer-fighting therapeutics
December 13, 2018 - Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
December 13, 2018 - Study explores how patients want to discuss symptoms with doctors
December 13, 2018 - RUDN medics first to gather scattered data on hepatitis morbidity in Somalia
December 13, 2018 - Age and gender disparities found in use of bed nets to prevent malaria in sub-Saharan Africa
December 13, 2018 - Caffeine therapy benefits developing brains of premature babies
December 13, 2018 - New review focuses on electrospinning techniques used in musculoskeletal tissue engineering
December 13, 2018 - A new division focused on human immune system
December 13, 2018 - Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla (ZX008) in Dravet Syndrome
December 13, 2018 - BCR ABL Genetic Test: MedlinePlus Lab Test Information
December 13, 2018 - Caffeinated beverages during pregnancy linked to lower birth weight babies
December 13, 2018 - Stanford Medicine Health Trends Report examines opportunity to democratize health care
December 13, 2018 - Obsessive-compulsive disorder may protect individuals from obesity
December 13, 2018 - Scientists investigate how a painful event is processed in the brain
December 13, 2018 - Genetic study reveals new insights into underlying causes of moderate-to-severe asthma
December 13, 2018 - Vitamin C supplementation for pregnant smokers may reduce harm to infants’ lungs
December 13, 2018 - New study reveals yin-yang personality of dopamine
December 13, 2018 - Children with high levels of callous traits show widespread differences in brain structure
December 13, 2018 - Long-term Benefit of Steroid Injections for Knee Osteoarthritis Challenged
December 13, 2018 - Adding new channels to the brain remote control
December 13, 2018 - In the Spotlight: A different side of neuroscience
December 13, 2018 - Medical Marvels: Using immunotherapy for melanoma that spread to the brain
December 13, 2018 - Puzzles do not keep dementia away finds study
December 13, 2018 - New mouse model shows potential for rapid identification of promising muscular dystrophy therapies
December 13, 2018 - Study reveals urban and rural differences in prenatal exposure to essential and toxic elements
December 13, 2018 - New collaborative partnership in quest of novel antibiotics
December 13, 2018 - Single tau molecule holds clues to help diagnose neurodegeneration in its earliest stages
December 13, 2018 - AHA Scientific Statement: Low Risk of Side Effects for Statins
December 13, 2018 - What Is Acute Flaccid Myelitis?
December 13, 2018 - How bereaved people control their thoughts without knowing it
December 13, 2018 - Health care democratization underway, according to 2nd annual Stanford Medicine Health Trends Report | News Center
December 13, 2018 - Going Beyond a Single Color
December 13, 2018 - London-based startup launches ‘thedrug.store’ aiming to clean up CBD industry
December 13, 2018 - Loss of tight junction barrier protein results in gastric cancer development
December 13, 2018 - Novel way to efficiently deliver anti-parasitic medicines
December 13, 2018 - RKI publishes new data on disease prevention and utilization of medical services
December 13, 2018 - High-tech, flexible patches sewn into clothes could help to stay warm
December 13, 2018 - The CCA releases three reports on requests for medical assistance in dying
December 13, 2018 - Restoring Hair Growth on Scarred Skin? Mouse Study Could Show the Way
December 13, 2018 - Probiotic use may reduce antibiotic prescriptions, researchers say
December 13, 2018 - Drug repositioning strategy identifies potential new treatments for epilepsy
December 13, 2018 - Chronic rhinitis associated with hospital readmissions for asthma and COPD patients
December 13, 2018 - Food poisoning discovery could save lives
December 13, 2018 - Cloned antibodies show potential to treat, diagnose life-threatening fungal infections
December 13, 2018 - Exercise may reduce colorectal cancer risk after weight loss
December 13, 2018 - Russian scientists create hardware-information system for brain disorders treatment
December 13, 2018 - Moderate alcohol consumption linked with lower risk of hospitalization
December 13, 2018 - Nurturing Healthy Neighborhoods | NIH News in Health
December 13, 2018 - Rise in meth and opioid use during pregnancy
December 13, 2018 - Researchers gain new insights into pediatric tumors
December 13, 2018 - FSU study finds racial disparity among adolescents receiving flu vaccine
December 13, 2018 - Study investigates attitudes toward implementation of ‘sex as a biological variable’ policy
December 13, 2018 - Drug cocktail induces cancer cell death by switching off energy supply
December 13, 2018 - Baculovirus virion completely eliminates liver-stage parasites in mouse model
December 13, 2018 - Researchers create noninvasive technology that detects when nerve cells fire
December 13, 2018 - Allen Institute for Immunology to partner with CU Anschutz to understand dynamics of human immune system
December 13, 2018 - Inability to do daily living tasks delays discharge of mental health patients
December 13, 2018 - Treating patients with hypertension induced albuminuria
December 13, 2018 - New substance could improve efficacy of established breast cancer treatments
December 13, 2018 - Scientists develop new stem cell line to study conversion of stem cells into muscle
December 13, 2018 - Re-programming the body’s energy pathway boosts kidney self-repair
December 13, 2018 - Research findings could help improve treatment of anxiety and post-traumatic stress disorders
December 13, 2018 - The Microbiome Movement announce Microbiotica as official industry partner
December 13, 2018 - New study reveals potential benefits of cEEG monitoring for infant ICU patients
December 13, 2018 - Whole-body imaging PET/MRI offers information to guide treatment options for prostate cancer
December 13, 2018 - International investigators fight against the negative campaign on benzodiazepines
December 13, 2018 - Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders
December 13, 2018 - FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections
December 13, 2018 - Are scientists studying the wrong kind of mice?
December 13, 2018 - Computer memory: A scientific team builds a virtual model of a key brain region
December 13, 2018 - Visual inspection alone is insufficient to diagnose skin cancer
December 13, 2018 - Paternal grandfather’s access to food associated with grandson’s mortality risk
December 13, 2018 - Our brain senses angry voices in a flash, study shows
December 13, 2018 - PM2.5 Exposure Linked to Asthma Rescue Medication Use
December 13, 2018 - Can’t exercise? A hot bath may help improve inflammation, metabolism, study suggests
December 13, 2018 - Can artificial intelligence help doctors with the human side of medicine?
December 13, 2018 - Virginia Tech and UC San Diego researchers team up to develop nonopioid drug for chronic pain
December 13, 2018 - NIH offers support for HIV care and prevention research in the southern United States
December 12, 2018 - Activating brain region could revive the urge to socialize among opioid addicts
December 12, 2018 - Relationship impairment appears to interfere with seeking mental health treatment in men
New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies

New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies

image_pdfDownload PDFimage_print

A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BCRA-mutated and triple negative cancers. New research from two studies conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania, are presented on today at the 2018 San Antonio Breast Cancer Symposium.

Today, some breast cancer patients with BRCA mutations and triple negative cancers are treated with Poly (ADP-ribose) Polymerase (PARP) inhibitors, which trap and destroy PARP-1, an important enzyme for DNA repair that cancer cells rely on for survival. Similarly, therapeutics that target glutaminase, an enzyme feeding some triple negative breast cancers, are also being developed. However, no method currently exists to measure these enzyme expression levels in patients. Having a biomarker to quantify those levels would help identify those most likely to benefit from targeted therapies in a non-invasive way.

In the first study (Abstract #851093), researchers from the Penn’s department of Radiology and the Abramson Cancer Center used PET imaging and a novel radioactive tracer known as [18F]FluorThanatrace (FTT), to measure PARP-1 levels in 30 women with breast cancer with various subtypes before therapy, including surgery.

FTT – which was developed by co-senior author Robert H. Mach, PhD, the Britton Chance Professor of Radiology at Penn – binds to PARP-1, making it visible on a PET scan. The researchers correlated the FTT uptake in the breast cancer patients with untreated surgical specimens that had been immunostained for PARP-1 in the lab. They found that the PET imaging agent could effectively visualize and measure PARP-1 levels in all breast cancer tumors and metastases.

Past studies from the same team of researchers have linked PARP-1 levels to targeted therapy resistance and shown FTT’s ability to quantify PARP expression levels in ovarian cancer.

“This study provides early validation of FTT as a quantitative method to measure PARP-1 expression in breast cancer,” said first author Elizabeth McDonald, MD, PhD, an assistant professor of Radiology at Penn. “Importantly, it also shows that the level of PARP-1 expression varies considerably within a given breast cancer subtype and that, surprisingly, any subtype can have high PARP-1 expression.”

Many clinical trials with PARP-1 have focused solely on the triple negative subtype. However, this new study suggests that some patients with ER positive cancers, for example, may have high levels of PARP-1 and thus may benefit from this targeted therapy.

What’s more, the results provide anecdotal evidence that expression levels can vary considerably in BRCA mutation carriers, too, which is important since BRCA status is often used as a criterion for selecting PARP inhibitor therapy, McDonald said.

In the second study (Abstract #851760), another team of researchers from Penn’s department of Radiology used a radioactive tracer, fluciclovine, as an imaging agent to measure tumor glutamine levels by PET imaging in mouse models of breast cancer based on the knowledge that some triple negative breast cancers rely on glutamine for survival and growth.

While fluciclovine PET has been approved by FDA for imaging prostate cancer, its abilities in other cancers are less known. This agent enters and exits cells via glutamine transporters and undergoes minimal metabolism.

Penn researchers unitized this imaging agent to observe what effect a glutaminase inhibitor (CB-839) would have on glutamine level in triple negative breast cancer. Glutaminase is considered a “druggable” target because it is a key enzyme of glutaminolysis, the pathway that cancer cell uses to metabolize glutamine and small molecule drugs.

“Assessing the tumor glutamine pool size will inform the pharmacological effect of glutaminase inhibitors because the treatment induces an increase of tumor glutamine level,” said senior author Rong Zhou, PhD, a research associate professor of Radiology at Penn. “This imaging approach can potentially provide a precision medicine tool that can tell physicians early on which patients are responding and which are not.”

The researchers showed that fluciclovine could effectively track the change of tumor glutamine level in response to glutaminase inhibition. For example, cellular uptake of fluciclovine was increased after CB-839 was administered, consistent with a higher concentration of glutamine in the triple negative breast cancer cells and a lower level of the enzyme activity.

Compared to chemotherapy, which usually shrinks tumors quickly and can be assessed by measuring the tumor size, metabolic drugs, such as glutaminase inhibitors, take longer to affect tumor size. Therefore, a non-invasive method that detects the early response to these drugs would be useful, Zhou said.

“These studies are important steps toward developing much-needed, non-invasive imaging tests to help measure and predict inhibitor responses and guide treatments for women with a wide range of breast cancers,” said David Mankoff, MD, PhD, the Gerd Muehllehner Professor of Radiology at Penn, and co-senior author on both abstracts. “Ongoing studies at Penn will continue to expand on these results and help move us closer to potential clinical application.”

Source:

https://www.pennmedicine.org/news/news-releases/2018/december/new-imaging-tools-that-trace-key-breast-cancer-enzymes-may-help-guide-therapies-dec

Tagged with:

About author

Related Articles